Psoriasis vulgaris flare during efalizumab therapy does not preclude future use

A case series

Michelle A. Lowes, James A. Turton, James G. Krueger, Ross St C Barnetson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD IIa), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α). Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.

Original languageEnglish (US)
Article number9
JournalBMC Dermatology
Volume5
DOIs
StatePublished - Aug 18 2005
Externally publishedYes

Fingerprint

Psoriasis
Biological Therapy
Therapeutics
Health Personnel
efalizumab

ASJC Scopus subject areas

  • Medicine(all)
  • Dermatology

Cite this

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use : A case series. / Lowes, Michelle A.; Turton, James A.; Krueger, James G.; Barnetson, Ross St C.

In: BMC Dermatology, Vol. 5, 9, 18.08.2005.

Research output: Contribution to journalArticle

Lowes, Michelle A. ; Turton, James A. ; Krueger, James G. ; Barnetson, Ross St C. / Psoriasis vulgaris flare during efalizumab therapy does not preclude future use : A case series. In: BMC Dermatology. 2005 ; Vol. 5.
@article{4adc87275aca48429f5e1cfd7287fdd6,
title = "Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: A case series",
abstract = "Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD IIa), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α). Conclusion: These cases are presented to characterize this {"}flare{"} reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.",
author = "Lowes, {Michelle A.} and Turton, {James A.} and Krueger, {James G.} and Barnetson, {Ross St C}",
year = "2005",
month = "8",
day = "18",
doi = "10.1186/1471-5945-5-9",
language = "English (US)",
volume = "5",
journal = "BMC Dermatology",
issn = "1471-5945",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Psoriasis vulgaris flare during efalizumab therapy does not preclude future use

T2 - A case series

AU - Lowes, Michelle A.

AU - Turton, James A.

AU - Krueger, James G.

AU - Barnetson, Ross St C

PY - 2005/8/18

Y1 - 2005/8/18

N2 - Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD IIa), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α). Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.

AB - Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD IIa), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α). Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.

UR - http://www.scopus.com/inward/record.url?scp=27644598182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644598182&partnerID=8YFLogxK

U2 - 10.1186/1471-5945-5-9

DO - 10.1186/1471-5945-5-9

M3 - Article

VL - 5

JO - BMC Dermatology

JF - BMC Dermatology

SN - 1471-5945

M1 - 9

ER -